Home » EMEA Issues Guideline on SmPC for Human Fibrinogen
EMEA Issues Guideline on SmPC for Human Fibrinogen
March 17, 2009
The summary of product characteristics (SmPC) for human fibrinogen used for the treatment and prophylaxis of patients with certain blood-clotting disorders should include the marketing authorization holder and a visual description of the product, according to a final guideline.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor